25 November 2020
The European Union has struck a deal for up to 160 million doses of U.S. firm Moderna’s COVID-19 vaccine candidate, the head of the European Commission said on Tuesday (24 November), taking the EU’s potential stock of COVID-19 shots to nearly 2 billion.
“I am happy to announce that tomorrow we will approve a new contract to secure another COVID-19 vaccine,” Ursula von der Leyen said, adding the deal “allows us to buy up to 160 million doses of a vaccine produced by Moderna.”
Actual purchases will be carried out by EU governments if the vaccine is approved by the EU’s drug regulator.
The delivery timeline is unknown. The doses would be enough to vaccinate 80 million people as the vaccine is expected to be administered in two doses.
The terms of the contract have not been disclosed.
An EU official involved in the talks told Reuters last week the EU was seeking a price below $25 per dose for Moderna’s vaccine.
But Moderna Chief Executive Stephane Bancel said the company would charge governments between $25 and $37 per dose, depending on the amount ordered.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Putin has stated that Russia will support Africa in the struggle against epidemics
19 April 2024
The Russian government has expanded the list of vital and essential drugs
19 April 2024
Achieving FAIR bacterial identification
18 April 2024
Unique testing regimen could prevent nuclease contamination
18 April 2024